Recent Quotes
My Watchlist
Indicators
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroBiologics, Inc. - Common Stock (NQ:FBLG)

1.310 -0.010 (-0.77%)
Streaming Delayed Price Updated: 3:06 PM EDT, Apr 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,162,029
Open 1.070
Bid (Size) 1.300 (600)
Ask (Size) 1.310 (400)
Prev. Close 1.320
Today's Range 1.030 - 1.590
52wk Range 0.1850 - 3.965
Shares Outstanding 38,262,586
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Which stocks are moving before the opening bell on Wednesday? ↗
Via Chartmill
News headline image
FibroBiologics Announces Pricing of $3 Million Public Offering
From FibroBiologics, Inc.
Via GlobeNewswire

Performance

YTD
+446.0%
+446.0%
1 Month
+212.3%
+212.3%
3 Month
+441.5%
+441.5%
6 Month
+139.8%
+139.8%
1 Year
+45.5%
+45.5%

More News

Read More
Top movers in Tuesday's after hours session ↗
Via Chartmill
News headline image
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
From FibroBiologics, Inc.
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
The market is filled with gapping stocks in Tuesday's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
From USA News Group
Via GlobeNewswire
News headline image
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at the BIO Investment & Growth Summit
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Granted Extension by Nasdaq to Regain Compliance
From FibroBiologics, Inc.
Via GlobeNewswire
Get insights into the top gainers and losers of Wednesday's after-hours session. ↗
Via Chartmill
News headline image
FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at the DealFlow Discovery Conference
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics CEO Issues Letter to Shareholders
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is FibroBiologics, Inc. - Common Stock publicly traded?
Yes, FibroBiologics, Inc. - Common Stock is publicly traded.
What exchange does FibroBiologics, Inc. - Common Stock trade on?
FibroBiologics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for FibroBiologics, Inc. - Common Stock?
The ticker symbol for FibroBiologics, Inc. - Common Stock is FBLG on the Nasdaq Stock Market
What is the current price of FibroBiologics, Inc. - Common Stock?
The current price of FibroBiologics, Inc. - Common Stock is 1.310
When was FibroBiologics, Inc. - Common Stock last traded?
The last trade of FibroBiologics, Inc. - Common Stock was at 04/01/26 03:06 PM ET
What is the market capitalization of FibroBiologics, Inc. - Common Stock?
The market capitalization of FibroBiologics, Inc. - Common Stock is 50.12M
How many shares of FibroBiologics, Inc. - Common Stock are outstanding?
FibroBiologics, Inc. - Common Stock has 50M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>